期刊
CURRENT PHARMACEUTICAL DESIGN
卷 16, 期 19, 页码 2113-2117出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161210791516440
关键词
Alcohol dependence; GABA; baclofen; alcohol craving; alcohol abstinence; heavy drinking; alcohol withdrawal; alcoholic cirrhosis
资金
- European Foundation for Alcohol Research (ERAB)
Preclinical studies show that antagonism of the GABA(B) receptor may represent an effective neuropharmacological approach to treat alcohol dependence. Consistent with preclinical evidence, the majority of the human studies have demonstrated that the prototype GABAB receptor antagonist baclofen may represent an effective mediation to treat alcohol-dependent individuals. Specifically, baclofen has shown to reduce alcohol withdrawal symptoms, as well as to reduce alcohol craving and intake, and to promote alcohol abstinence. Notably, baclofen has shown a safe profile when administered to alcoholics, including those with liver cirrhosis. In summary, baclofen represents a safe and effective medication to treat alcohol dependence, thus holding promise as a new pharmacotherapy. However, large studies are needed to confirm the present findings.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据